Skip Navigation



Glycobiology Advance Access published online on September 26, 2003
Glycobiology, doi:10.1093/glycob/cwh010
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
14/1/51    most recent
cwh010v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Koles, K.
Right arrow Articles by Kamerling, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koles, K.
Right arrow Articles by Kamerling, J. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Submitted on July 22, 2003
Revised on September 10, 2003
Accepted on September 11, 2003

© 2003 Oxford University Press

ORIGINAL ARTICLES

N- and O-glycans of recombinant human C1 Inhibitor expressed in the milk of transgenic rabbits

Kate Koles 1, Patrick H. C. van Berkel 2, Frank R. Pieper 2, Jan H. Nuijens 2, Maurice L. M. Mannesse 2, Johannes F. G. Vliegenthart 1, and Johannis P. Kamerling 1*

1 Bijvoet Center for Biomolecular Research, Department of Bio-Organic Chemistry, Section of Glycoscience and Biocatalysis, Utrecht University, Padualaan 8, NL-3584 CH Utrecht, The Netherlands
2 Pharming Technologies BV, Archimedesweg 4, P.O. Box 451, NL-2300 AL Leiden, The Netherlands

* To whom correspondence should be addressed. E-mail: j.p.kamerling{at}chem.uu.nl.

Abstract

Human C1 Inhibitor (hC1INH) is a therapeutic N,O-glycoprotein with a growing number of clinical applications, but the current natural supplies are not likely to meet the clinical demands. Therefore, recombinant approaches are of interest, whereby specific attention has to be paid to the generated glycosylation patterns. Here, the N,O-glycoprotein was expressed in the mammary gland of transgenic rabbits, and subjected to glycan analysis. After release of the N-glycans of recombinant-rabbit human C1 Inhibitor (rhC1INH) by peptide-N4-(N-acetyl-{beta}-glucosaminyl)asparagine amidase F, the oligosaccharides were separated from the O-glycoprotein by centrifugal filtration, then fractionated by a combination of anion-exchange, normal-phase and high-pH anion-exchange LC. The O-glycans, released from the O-glycoprotein by alkaline borohydride treatment, were fractionated by anion-exchange HPLC. The structures of individual components were analysed by 500 MHz 1H NMR spectroscopy, in most cases combined with MALDI-TOF mass spectrometry. In contrast to the structural data reported for native serum hC1INH, rhC1INH contained a broad array of different N-glycans, comprising oligomannose-, hybrid-, and complex-type structures. In the case of complex-type N-glycans (partially) ({alpha}2-6)-sialylated (N-acetylneuraminic acid only), mono- and diantennary chains were found; part of the diantennary structures were ({alpha}1-6)-core-fucosylated or ({alpha}1-3)-fucosylated in the lower or upper antenna (Lewis X). The manno-oligosaccharide pattern of part of the hybrid- and oligomannose-type structures indicates that, besides the usual N-glycan processing route, also the alternative endo-mannosidase pathway is followed. The small core 1-type O-glycans showed the usual ({alpha}2-3)- and ({alpha}2-6)-sialylation pattern of O-glycoproteins of non-mucinous origin.


transgenic rabbit milk, glycosylation, C1 Inhibitor
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 GlycobiologyHome page
G.-C. Gil, W. H Velander, and K. E Van Cott
Analysis of the N-glycans of recombinant human Factor IX purified from transgenic pig milk
Glycobiology, July 1, 2008; 18(7): 526 - 539.
[Abstract] [Full Text] [PDF]

Home page
 Plant Physiol.Home page
A. Garcia-Pino, L. Buts, L. Wyns, A. Imberty, and R. Loris
How a Plant Lectin Recognizes High Mannose Oligosaccharides
Plant Physiology, August 1, 2007; 144(4): 1733 - 1741.
[Abstract] [Full Text] [PDF]

Home page
 GlycobiologyHome page
S. P Jongen, G. J Gerwig, B. R Leeflang, K. Koles, M. L. Mannesse, P. H. van Berkel, F. R Pieper, M. A Kroos, A. J. Reuser, Q. Zhou, et al.
N-glycans of recombinant human acid {alpha}-glucosidase expressed in the milk of transgenic rabbits
Glycobiology, June 1, 2007; 17(6): 600 - 619.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
S. Legardinier, M. Duonor-Cerutti, G. Devauchelle, Y. Combarnous, and C. Cahoreau
Biological activities of recombinant equine luteinizing hormone/chorionic gonadotropin (eLH/CG) expressed in Sf9 and Mimic insect cell lines
J. Mol. Endocrinol., February 1, 2005; 34(1): 47 - 60.
[Abstract] [Full Text] [PDF]

Home page
 GlycobiologyHome page
K. Koles, P. H.C. van Berkel, M. L.M. Mannesse, R. Zoetemelk, J. F.G. Vliegenthart, and J. P. Kamerling
Influence of lactation parameters on the N-glycosylation of recombinant human C1 inhibitor isolated from the milk of transgenic rabbits
Glycobiology, November 1, 2004; 14(11): 979 - 986.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.